Dynavax, a commercial stage biopharmaceutical company developing and commercialising novel vaccines, reported on Thursday its financial results for the first quarter of 2021.

The company reported total revenue for the first quarter of 2021 at USD83.3m compared to USD10.9m for the first quarter of 2020.

The firm posted income from operations for the first quarter of 2021 at USD28.5m compared to a loss of USD19.3m for the year-ago period. Net income for the first quarter of 2021 at USD0.9m compared to a net loss of USD12.6m for the same period in 2020. The firm posted basic and diluted net income per share at USD0.01 for the first quarter of 2021, compared to a basic net loss of USD0.15 per share and diluted net loss per share of USD0.25 in the first quarter of 2020.

'The first quarter of 2021 continued to build on our successful execution in 2020. With the combined strength of opportunities from HEPLISAV-B and CpG 1018, we believe 2021 will be a transformational year for Dynavax,' commented Dynavax chief executive officer Ryan Spencer.